Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1

Conditions

Multiple Myeloma 1Leukemia, Plasma Cell 1

Interventions

venetoclax 74Specimen Handling 69Cyclophosphamide 61Cytarabine 52Biopsy 51fludarabine 45Azacitidine 38Rituximab 28fludarabine phosphate 22Methotrexate 22Vincristine 21Magnetic Resonance Spectroscopy 21blinatumomab 20Daunorubicin 20Prednisone 19Dexamethasone 17ibrutinib 16Whole-Body Irradiation 16Injections 16decitabine and cedazuridine drug combination 15Tacrolimus 14Mycophenolic Acid 14Melphalan 14Doxorubicin 14Busulfan 14obinutuzumab 13merphos 13acalabrutinib 13Mercaptopurine 13Granulocyte Colony-Stimulating Factor 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
High-Throughput Screening Assays × Other hematologic neoplasm × 30 days × Clear all
NCT03389347 2026-05-08

High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

University of Washington

Phase NA Active not recruiting
40 enrolled 7 charts
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡